Brokerages Anticipate Alnylam Pharmaceuticals, Inc. (ALNY) Will Post Quarterly Sales of $26.90 Million

Wall Street brokerages expect that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will post sales of $26.90 million for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Alnylam Pharmaceuticals’ earnings. The highest sales estimate is $42.38 million and the lowest is $17.10 million. Alnylam Pharmaceuticals posted sales of $17.45 million during the same quarter last year, which would indicate a positive year over year growth rate of 54.2%. The business is expected to issue its next quarterly earnings report on Wednesday, February 14th.

On average, analysts expect that Alnylam Pharmaceuticals will report full year sales of $26.90 million for the current fiscal year, with estimates ranging from $56.59 million to $94.36 million. For the next financial year, analysts expect that the firm will report sales of $86.89 million per share, with estimates ranging from $13.74 million to $137.00 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). The business had revenue of $17.10 million during the quarter, compared to analysts’ expectations of $28.15 million. Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. Alnylam Pharmaceuticals’s revenue for the quarter was up 24.8% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.21) EPS.

A number of analysts have recently issued reports on ALNY shares. Credit Suisse Group increased their target price on Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the company an “outperform” rating in a report on Friday, November 3rd. Piper Jaffray Companies restated an “overweight” rating and issued a $14.71 target price (down previously from $188.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, November 2nd. B. Riley started coverage on Alnylam Pharmaceuticals in a report on Wednesday, November 1st. They issued a “buy” rating and a $240.00 target price for the company. Goldman Sachs Group upgraded Alnylam Pharmaceuticals from a “buy” rating to a “conviction-buy” rating in a report on Friday, December 15th. Finally, FBR & Co started coverage on Alnylam Pharmaceuticals in a report on Monday, October 30th. They issued a “buy” rating and a $150.00 target price for the company. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. Alnylam Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $121.20.

In related news, SVP Laurie Keating sold 6,249 shares of the stock in a transaction on Wednesday, December 20th. The stock was sold at an average price of $121.20, for a total transaction of $757,378.80. Following the completion of the sale, the senior vice president now directly owns 17,749 shares in the company, valued at $2,151,178.80. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Akshay Vaishnaw sold 33,666 shares of the stock in a transaction on Monday, October 30th. The stock was sold at an average price of $121.46, for a total value of $4,089,072.36. Following the sale, the executive vice president now owns 45,201 shares of the company’s stock, valued at $5,490,113.46. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 274,075 shares of company stock valued at $35,356,089. 4.30% of the stock is owned by corporate insiders.

Several large investors have recently made changes to their positions in ALNY. Livforsakringsbolaget Skandia Omsesidigt bought a new position in Alnylam Pharmaceuticals during the fourth quarter valued at about $165,000. QS Investors LLC raised its holdings in Alnylam Pharmaceuticals by 59.7% during the second quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 900 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in Alnylam Pharmaceuticals by 7.0% during the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 167 shares in the last quarter. Neuberger Berman Group LLC bought a new position in Alnylam Pharmaceuticals during the second quarter valued at about $229,000. Finally, Fayerweather Charles bought a new position in Alnylam Pharmaceuticals during the third quarter valued at about $230,000. Institutional investors and hedge funds own 88.39% of the company’s stock.

Alnylam Pharmaceuticals (NASDAQ ALNY) traded up $0.84 on Thursday, hitting $124.83. The stock had a trading volume of 840,670 shares, compared to its average volume of 866,472. The stock has a market capitalization of $12,270.00, a price-to-earnings ratio of -23.78 and a beta of 2.98. Alnylam Pharmaceuticals has a one year low of $35.98 and a one year high of $147.63. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.83 and a quick ratio of 9.83.

COPYRIGHT VIOLATION NOTICE: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.com-unik.info/2018/01/21/brokerages-anticipate-alnylam-pharmaceuticals-inc-alny-will-post-quarterly-sales-of-26-90-million.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit